Prediction of Opioid Use Duration in Post-Surgical Orthopedic Patients Using CYP2D6 Inhibitor Index and Routine Laboratory Markers

被引：0
|
作者：
Miller, H. A. [1 ]
Whitt, A. G. [1 ]
Gaskins, J. [1 ]
Renfrow, R. E. [1 ]
Hartley, B. [1 ]
McMillin, G. A. [2 ]
Jortani, S. A. [1 ]
机构：
[1] Univ Louisville, Louisville, KY USA
[2] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA
来源：
CLINICAL CHEMISTRY | 2024年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
B-123
引用
收藏
页数：2
相关论文
共 6 条
  • [1] Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain
    Casajus, Ana
    Zubiaur, Pablo
    Alday, Enrique
    Soria-Chacartegui, Paula
    Saiz-Rodriguez, Miriam
    Gutierrez, Lara
    Aragones, Catalina
    Campodonico, Diana
    Gomez-Fernandez, Antia
    Navares-Gomez, Marcos
    Villapalos-Garcia, Gonzalo
    Mejia-Abril, Gina
    Ochoa, Dolores
    Abad-Santos, Francisco
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (01):
  • [2] CONCOMITANT CYP2D6 INHIBITOR USE AND PLASMA METABOLITE LEVELS IN BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN
    Fox, P.
    Balakrishnar, B.
    Menzies, A.
    Liddle, C.
    Coulter, S.
    Provan, P.
    Gebski, V.
    Hui, R.
    Kefford, R.
    Wilcken, N.
    Balleine, R.
    Gurney, H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 52 - 52
  • [3] The effect of a tamoxifen dose increase from 20 mg to 40 mg in patients with at least one inactive CYP2D6 variant allele and/or concomitant use of a CYP2D6 inhibitor.
    Welzen, M. E. B.
    Dezentje, V. O.
    van Schaik, R. H. N.
    Colbers, E. P. H.
    Guchelaar, H.
    den Hartigh, J.
    Burger, D. M.
    Van Laarhoven, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
    Opdam, F. L.
    Dezentje, V. O.
    den Hartigh, J.
    Modak, A. S.
    Vree, R.
    Batman, E.
    Smorenburg, C. H.
    Nortier, J. W. R.
    Gelderblom, H.
    Guchelaar, H. -J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 593 - 601
  • [5] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
    F. L. Opdam
    V. O. Dezentje
    J. den Hartigh
    A. S. Modak
    R. Vree
    E. Batman
    C. H. Smorenburg
    J. W. R. Nortier
    H. Gelderblom
    H.-J. Guchelaar
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 593 - 601
  • [6] Erratum to: The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
    F. L. Opdam
    V. O. Dezentje
    J. den Hartigh
    A. S. Modak
    R. Vree
    E. Batman
    C. H. Smorenburg
    J. W. R. Nortier
    H. Gelderblom
    H.-J. Guchelaar
    Cancer Chemotherapy and Pharmacology, 2013, 71 (3) : 603 - 603
1